Veterinary Medicines

P3-RHINOPLUS

Authorised
  • Turkey rhinotracheitis virus, strain VCO3, Inactivated
  • Newcastle disease virus, strain Ulster 2C, Inactivated
  • Avian paramyxovirus 3, strain PMV3, Inactivated
Download as PDF

Identifikacija zdravila

Ime zdravila:
P3-RHINOPLUS
Učinkovina:
Ciljne živalske vrste:
Pot uporabe:
  • Subkutana uporaba

Podatki o zdravilu

Učinkovina / Jakost:
  • Na voljo samo v English
    5.00
    log10 tissue culture infective dose 50
    /
    0.50
    millilitre(s)
  • Na voljo samo v English
    8.00
    log 10 50% embryo infective dose
    /
    0.50
    millilitre(s)
  • Na voljo samo v English
    6.70
    log 10 50% embryo infective dose
    /
    0.50
    millilitre(s)
Farmacevtska oblika:
  • Emulzija za injiciranje
Withdrawal period by route of administration:
  • Subcutaneous use
    • Turkey
      • Meat and offal
        0
        day
Anatomsko-terapevtsko-kemična veterinarska oznaka (ATCvet):
  • QI01CA02
Pravni status za dobavo / izdajo zdravila:
  • Zdravilo, ki se izdaja na veterinarski recept
Status dovoljenja:
  • Valid
Authorised in:
Ta podatek za to zdravilo ni na voljo.
Opis ovojnine:

Dodatne informacije

Entitlement type:
Pravna podlaga za izdajo dovoljenja za promet z zdravilom:
Imetnik dovoljenja za promet z zdravilom:
  • Boehringer Ingelheim Animal Health Italia S.p.A. In Breve Boehringer Ingelheim Ah It S.p.A.
Marketing authorisation date:
Proizvodna mesta, odgovorna za sproščanje serij:
  • Boehringer Ingelheim Animal Health Italia S.p.A.
Pristojni organ:
  • MdS
Številka dovoljenja :
Ta podatek za to zdravilo ni na voljo.
Datum spremembe statusa dovoljenja:

Dokumenti

Combined File of all Documents

Ta dokument ne obstaja v tem jeziku (slovenščina). Spodaj ga najdete v drugem jeziku.
Italian (PDF)
Objavljeno na: 6/03/2023
Prenesi
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."